Pancreatic Cancer Research

ResearcherChang Gung UniversityActive in the last 2 years

Yen‐Yang Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5450-5045; OpenAlex author ID A5001467169. Sources: OpenAlex.

Their work

Papers
22 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2018: 2 papers · 2019: 5 papers · 2020: 2 papers · 2021: 2 papers · 2022: 6 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 22

  1. Third-line platinum-based chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jfma.2026.01.057↗
  2. The efficacy and safety profile of third-line treatment in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2025.01.012↗
  3. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation. Co-author DOI 10.1016/j.bj.2023.100696↗
  4. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.03.014↗
  5. Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers15041008↗
  6. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovo… Co-author DOI 10.1002/jhbp.1128↗
  7. A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma - T… Co-author DOI 10.1016/j.ejca.2022.06.043↗
  8. Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. Co-author DOI 10.3389/fonc.2022.800842↗
  9. The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan. Co-author PMID 35530292↗
  10. Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma rec… Co-author PMID 36225629↗
  11. The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic duc… Co-author PMID 36504882↗
  12. Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study. Co-author DOI 10.1177/17588359211058255↗
  13. Downregulation of Notch3 links TIMP3 inhibition to suppress aggressive phenotypes of pancreatic ductal adenocarcinoma. Co-author PMID 34873483↗
  14. External validation of the Besançon nomogram in Asian patients with advanced pancreatic cancer receiving second-line chemotherapy: A multi-institute experience… Co-author DOI 10.1016/j.pan.2019.11.001↗
  15. Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second-line palliative chemothera… Co-author DOI 10.1111/jgh.14926↗
  16. Effect of S-1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7-year multicenter observational cohort study in Taiwan. First author DOI 10.1002/cam4.2094↗
  17. Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic … Co-author DOI 10.1002/cam4.2254↗
  18. Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy. Co-author DOI 10.1002/cam4.2483↗
  19. Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010-2… First author DOI 10.2147/cmar.s196300↗
  20. Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model. Co-author DOI 10.3390/cancers11010057↗
  21. Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy. Co-author DOI 10.3390/cancers10110432↗
  22. Venous Thromboembolism in Asian Patients with Pancreatic Cancer Following Palliative Chemotherapy: Low Incidence but a Negative Prognosticator for Those with E… Co-author DOI 10.3390/cancers10120501↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wen‐Chi Chou · 20 shared papers, 2018–2026 · strength 2.66
  2. Jen‐Shi Chen · 19 shared papers, 2018–2026 · strength 2.59
  3. Tai‐Jan Chiu · 12 shared papers, 2021–2026 · strength 1.92
  4. Nai‐Jung Chiang · 10 shared papers, 2021–2024 · strength 1.39
  5. Li‐Yuan Bai · 10 shared papers, 2021–2024 · strength 1.39
  6. Chung‐Pin Li · 10 shared papers, 2021–2024 · strength 1.39
  7. Yu‐Shin Hung · 10 shared papers, 2018–2026 · strength 1.30
  8. Shih‐Hung Yang · 9 shared papers, 2021–2024 · strength 1.25
  9. Yan‐Shen Shan · 9 shared papers, 2021–2024 · strength 1.20
  10. Yung‐Yeh Su · 8 shared papers, 2021–2024 · strength 1.12
  11. Li‐Tzong Chen · 8 shared papers, 2021–2024 · strength 1.07
  12. Cheng‐Ming Peng · 8 shared papers, 2021–2024 · strength 1.06
  13. Pei‐Hung Chang · 9 shared papers, 2018–2020 · strength 0.87
  14. Chi-Chen Lan · 2 shared papers, 2025–2026 · strength 0.54
  15. Chieh-Ying Chang · 1 shared paper, 2026 · strength 0.29
  16. Ching‐Fu Chang · 2 shared papers, 2019 · strength 0.19
  17. Pei‐Wei Huang · 2 shared papers, 2019 · strength 0.19
  18. Hsin‐Chen Lin · 1 shared paper, 2024 · strength 0.19
  19. Chien‐Jui Huang · 1 shared paper, 2024 · strength 0.19
  20. Cheng‐Yu Tang · 1 shared paper, 2024 · strength 0.17
  21. Chang‐Han Chen · 1 shared paper, 2021 · strength 0.13
  22. Keng-Hao Liu · 1 shared paper, 2020 · strength 0.11
  23. Shao‐Ming Yu · 1 shared paper, 2020 · strength 0.11
  24. Chih–Chung Hsu · 1 shared paper, 2020 · strength 0.11
  25. Shu‐Hui Lee · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.